BIO vs OPY · rev $2.58B vs P/E 13, rev $1.43B
BIO (BIO) versus Oppenheimer Holdings Inc (OPY) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Oppenheimer Holdings Inc (OPY) is a capital markets company listed on NYSE.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported OPY revenue for 2024-12-31 was $1.43B. Net income was $71.2M. Revenue was up 14.7% from 2023-12-31 to 2024-12-31. OPY currently screens at market cap $1.15B and trailing P/E 12.8.
BIO currently screens at market cap $0. OPY currently screens at market cap $1.15B and trailing P/E 12.8.
Not investment advice. Open the BIO and OPY stock pages for the full models.
Not investment advice.